Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer

American Journal of Pathology

Volumn 169, Issue 1, 2006, Pages 233-246

  Allan, Alison L ^a   George, Rosamma ^a,b   Vantyghem, Sharon A ^a   Lee, Mark W ^a,b   Hodgson, Nicole C ^b   Engel, C Jay ^a,b   Holliday, Ron L ^b   Girvan, David P ^b   Scott, Leslie A ^b   Postenka, Carl O ^a   Al Katib, Waleed ^a   Stitt, Larry W ^a,b   Uede, Toshimitsu ^c   Chambers, Ann F ^a   Tuck, Alan B ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BINDING PROTEIN; COMPLEMENTARY DNA; ESTROGEN RECEPTOR; INTEGRIN; OSTEOPONTIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL ADHESION; CELL GROWTH; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; SENTINEL LYMPH NODE; SITE DIRECTED MUTAGENESIS; TUMOR CELL; WESTERN BLOTTING;

EID: 33745700699     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.051152     Document Type: Article

References (78)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30
2. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572
3. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456
4. Fidler IJ: 7th Jan Waldenstrom Lecture. The biology of human cancer metastasis. Acta Oncol 1991, 30:668-675
5. MacDonald IC, Groom AC, Chambers AF: Cancer spread and micrometastasis development: quantitative approaches for in vivo models. BioEssays 2002, 24:885-893
6. Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer 1997, 80:1529-1537
7. Swartz MA, Skobe M: Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 2001, 55:92-99
8. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, Poisson R, Shibata H, Volk H: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983, 52:1551-1557
9. Foster RS, Jr: The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am 1996, 5:79-104
10. McGuire WL: Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987, 10:5-9
11. Sakorafas GH, Geraghty J, Pavlakis G: The clinical significance of axillary lymph node micrometastases in breast cancer. Eur J Surg Oncol 2004, 30:807-816
12. Sakorafas GH, Tsiotou AG: Sentinel lymph node biopsy in breast cancer. Am Surg 2000, 66:667-674
13. White RL, Jr., Wilke LG: Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg 2004, 70:420-424
14. Giuliano AE, Kirgan DM, Guenther JM, Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220:391-398, discussion 398-401
15. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL: Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995, 222:394-399, discussion 399-401
16. Giuliano AE, Jones RC, Brennan M, Statman R: Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997, 15:2345-2350
17. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Staging system for breast cancer: revisions for the ed 6 of the AJCC Cancer Staging Manual. Surg Clin North Am 2003, 83:803-819
18. Thor A: A revised staging system for breast cancer. J Breast 2004, 10(Suppl 1):S15-S18
19. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994, 145:610-623
20. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7:4060-4066
21. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002, 94:513-521
22. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997, 3:605-611
23. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF: Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 1997, 121:578-584
24. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998, 79:502-508
25. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF: Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002, 95:506-512
26. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC: Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004, 10:3474-3478
27. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184-190
28. Saeki Y, Mima T, Ishii T, Ogata A, Kobayashi H, Ohshima S, Ishida T, Tabunoki Y, Kitayama H, Mizuki M, Katada Y, Asaoku H, Kitano M, Nishimoto N, Yoshizaki K, Maeda M, Kon S, Kinoshita N, Uede T, Kawase I: Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol 2003, 123:263-270
29. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003, 9:59-67
30. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC: Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003, 98:119-127
31. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG: Osteopontin expression in lung cancer. Lung Cancer 1996, 15:311-323
32. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002, 62:3417-3427
33. Sodek J, Ganss B, McKee MD: Osteopontin. Crit Rev Oral Biol Med 2000, 11:279-303
34. Furger KA, Menon RK, Tuck AB, Bramwelll VH, Chambers AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001, 1:621-632
35. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF: Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995, 57:680-690
36. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246
37. Tuck AB, Hota C, Chambers AF: Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001, 70:197-204
38. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF: Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 2000, 78:465-475
39. Shijubo N, Uede T, Kon S, Nagata M, Abe S: Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 2000, 11:135-146
40. Tuck AB, Hota C, Wilson SM, Chambers AF: Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 2003, 22:1198-1205
41. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-Katib W, Chambers AF, Tuck AB: Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 2003, 1:810-819
42. Adwan H, Bauerle T, Najajreh Y, Elazer V, Golomb G, Berger MR: Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 2004, 24:1235-1244
43. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF: Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog 2005, 43:225-236
44. Rittling SR, Chambers AF: Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881
45. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS: Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061
46. Vantyghem SA, Allan AL, Postenka CO, Al-Katib W, Keeney M, Tuck AB, Chambers AF: A model for lymph node metastasis of breast cancer: characterization of a metastatic variant of the MDA-MB-468 human breast cancer cell line. Clin Exp Metastasis 2005, 22:351-361
47. Xuan JW, Hota C, Chambers AF: Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 1994, 54:247-255
48. Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF: Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994, 269:23280-23285
49. Kon S, Yokosaki Y, Maeda M, Segawa T, Horikoshi Y, Tsukagoshi H, Rashid MM, Morimoto J, Inobe M, Shijubo N, Chambers AF, Uede T: Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem 2002, 84:420-432
50. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85:200-206
51. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW: cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990, 7:491-502
52. Price JE, Polyzos A, Zhang RD, Daniels LM: Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990, 50:717-721
53. Cailleau R, Olive M, Cruciger QV: Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 1978, 14:911-915
54. Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF: Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res 2005, 65:3396-3403
55. Smith LL, Giachelli CM: Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res 1998, 242:351-360
56. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995, 95:713-724
57. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW: A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995, 270:26232-26238
58. Halstead WS: The results of operations for the cure of cancer of the breast performed at Johns Hopkins Hospitals. Ann Surg 1894, 20:497-504
59. Brown P: Lymphatic system: unlocking the drains. Nature 2005, 436:456-458
60. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG: LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999, 144:789-801
61. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425
62. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998, 95:548-553
63. Vlahakis NE, Young BA, Atakilit A, Sheppard D: The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem 2005, 280:4544-4552
64. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198
65. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002, 94:819-825
66. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001, 7:186-191
67. Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, Zurrida S, Maisonneuve P, Paganelli G, Mazzarol G: Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005, 241:319-325
68. Joseph KA, El-Tamer M, Komenaka I, Troxel A, Ditkoff BA, Schnabel F: Predictors of nonsentinel node metastasis in patients with breast cancer after sentinel node metastasis. Arch Surg 2004, 139:648-651
69. Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, Sandrucci S, Baltas B, Bussolati G: Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004, 91:1245-1252
70. Torrenga H, Fabry H, van der Sijp JR, van Diest PJ, Pijpers R, Meijer S: Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J Surg Oncol 2004, 88:4-7, discussion 7-8
71. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS, 3rd, Kattan MW: A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003, 10:1140-1151
72. Denhardt DT, Quo X: Osteopontin: a protein with diverse functions. FASEB J 1993, 7:1475-1482
73. Ruco LP, Pomponi D, Pigott R, Stoppacciaro A, Monardo F, Uccini S, Boraschi D, Tagliabue A, Santoni A, Dejana E: Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study Am J Pathol 1990, 137:1163-1171
74. O'Regan AW, Nau GJ, Chupp GL, Berman JS: Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000, 21:475-478
75. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999, 285:1028-1032
76. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D: The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 1999, 274:36328-36334
77. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T: CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999, 59:219-226
78. Weber GF, Ashkar S, Glimcher MJ, Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996, 271:509-512